investigation was warranted for a further 13 lesions with targeted imaging resolving the diagnosis in most cases. Subsequent annual WBMRIs did not detect any additional tumors, nor were interval cancers diagnosed clinically. Interestingly, 2 prostate cancers were diagnosed, prompting the addition of annual prostate-specific antigen to the protocol.
Mary-Anne Young, MSc, Garvan Institute of Medical Research, Sydney, Australia, for their invaluable contributions to reviewing scans, or clinical assessment of participants, contributions ordinarily worthy of authorship. They were not compensated for their assistance. Eveline Niedermayr, BSc, provided data management and Emma Galligan, BSc, coordinated recruitment and data collection. Both are paid employees of the Peter MacCallum Cancer Centre. Due to this broad spectrum, surveillance of TP53 mutation carriers is challenging and w h o l e -b o d y m a g n e t i c r e s o n a n c e i m a g i n g ( M R I ) represents an attractive strategy.
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Methods | To evaluate the pertinence of whole-body MRI, LIFSCREEN was designed as a national, multicenter randomized clinical trial. Participants were randomly allocated either to the standard screening procedures (clinical examination, abdomen and pelvis ultrasound, brain MRI, complete blood cell count, breast ultrasound and MRI for women >20 y) at inclusion and repeated yearly up to month 48, or to the same procedures with the addition of diffusion whole-body MRI. The main analysis on the primary end point is planned in 2017 when all participants will have at least 2 years of follow-up. We report here the cancers diagnosed so far in this large cohort of LFS families, regardless of the discovery modality.
Results | Overall, 107 participants, 78 females and 29 males belonging to 75 different families, were enrolled (Table) . The median age at inclusion was 32.9 years (range, 5-67 years). Fiftyone (48%) had a personal cancer history and 19 (18%) had developed more than 1 cancer. Chompret criteria for LFS 2 were fulfilled for 84 participants (79% were outside the usual LFS core spectrum, with the most frequent being lung adenocarcinomas (5 of 23 [22%]). The proportion and diversity of off-core LFS spectrum cancers detected in TP53 mutation carriers as reported by others 5, 6 give growing evidence of a broader LFS spectrum, in agreement with the permissive role of TP53 mutations. 2 Our observations seem to support recent moves toward broader cancer screening in TP53 mutation carriers. 6 Data collection in the LIFSCREEN study is still ongoing. Our final analysis will help to determine the benefits and drawbacks (mostly related to false-positive test results) of whole-body MRI in TP53 mutation carrier surveillance. Studies focused on TP53 mutation penetrance, using methods limiting selection bias, are required to refine cancer risks to improve TP53 mutation carrier management. 
